| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 35.07 | 16.8% |
| Total Income | 35.07 | 16.8% |
| Expenditure | 61.83 | 2.3% |
| PBT | -22.39 | 4.4% |
| Net Profit | -22.39 | 4.6% |
| OPM | -76.31% | |
| NPM | -63.86% | 14.31pp |
| EPS | -1.02 | 63.2% |
Karyopharm Reports Q1 2026 Revenue of $35.1 Million
14 May 2026 · 14 May, 5:06 pm
Summary
Karyopharm Therapeutics Inc. reported its financial results for the first quarter of 2026, with total revenue reaching $35.1 million, up from $30.0 million in the same period of 2025. U.S. XPOVIO net product revenue increased to $29.2 million from $21.1 million year-over-year. The company reaffirmed its full-year 2026 total revenue guidance of $130 million to $150 million. Karyopharm is anticipating topline data from the Phase 3 XPORT-EC-042 trial in endometrial cancer in mid-2026.
Key Highlights
- 1
Karyopharm's total revenue for the first quarter of 2026 was $35.1 million, compared to $30.0 million for the first quarter of 2025.
- 2
U.S. XPOVIO net product revenue was $29.2 million for the first quarter of 2026, compared to $21.1 million for the first quarter of 2025.
- 3
Royalty revenue increased to $1.9 million in the first quarter of 2026 compared to $1.7 million in the first quarter of 2025.
- 4
The company reaffirms full-year 2026 total revenue guidance of $130 million to $150 million.
- 5
Karyopharm completed enrollment of the Phase 3 XPORT-EC-042 trial in endometrial cancer, with topline data expected mid-2026.
- 6
Phase 3 SENTRY results in myelofibrosis were selected for a late-breaking oral presentation at ASCO on June 2.
Management Comments
Richard Paulson
As we move through 2026, Karyopharm is in a pivotal period with meaningful clinical and regulatory milestones ahead. Through the second and third quarters of 2026, we expect several important developments that have the potential to create significant value for the Company, while improving outcomes for patients. In endometrial cancer, we have completed enrollment in our Phase 3 XPORT-EC-042 trial and remain on track to report topline data in mid-2026. In myelofibrosis, the Phase 3 SENTRY results reinforced the potential of selinexor to meaningfully improve patient outcomes, including a statistically significant SVR35 benefit and a promising overall survival signal. With the endometrial cancer readout ahead and the myelofibrosis regulatory and guideline path coming into focus, we believe these programs could meaningfully expand the impact and long-term opportunity of the selinexor franchise.
Informational and educational content only. Not investment advice.